December 13, 2016 5:39pm

 

… You never get hurt by taking a profit in any overbought territory

To build a BUY account for the down-trodden who are oversold candidates

 

Pre-open indication’s tally:  7 hits (AGTC, BSTG, BTX, HSGX, XON and ONVO) and 1 miss (FATE)

 

 

There are two things that investors need - interpretation of news and translation of market metrics concerning the stem, cell, gene and regenerative therapy sector to substantiate share pricing.

 

I answer one question; in which company should investors put, keep and commit their money!

 

 

I say today what others won't, so you can do what others can't!

 

 

U.S. equities closed higher on Tuesday as investors kept an eye on a key Fed meeting, while the Dow closed in on another milestone.

The NASDAQ closed UP +51.29 or +0.95% to 5,463.83 and the DOW closed UP +114.78 or +0.58% to 19,911.21.

 

 

A day in the life of the stem, cell, gene and regenerative therapy (SCGT & RT) sector – the advance/decline line scenario of our 43 covered companies:   

  • The open was positive with an A/DL of 28/15 and 0 flat;                        
  • The mid-day was positive with an A/DL of 22/20 and 1 flat;
  • The closing bell was positive with A/DL of 21/19 and 3 flats;

 

 

Henry’omics:

The stem, cell, gene and regenerative therapy (SCG&RT) sector opened positive, stayed positive at the mid-day and closed positive.

  • From this morning’s investor’s letter, “good news … Regenerative medicine will help us age … better. Bad news, we have to start supporting and funding the initiatives.”

The newly passed, 21st Century Cures Act should allow for early patient access to cell therapies, while also creating medical and economic benefits for the U.S. healthcare system.”

  • Reiterating, everyone is constantly  second guessing what a Trump presidency will mean to the pharma, biotech and its young niece – cell therapy and nephew – regenerative medicine as some in the financial markets think that Trump’s personality is a match to kindling that could spell more growth and possibly inflation.

 

The iShares Russell 2000 (IWM) indicated a positive pre- open of +0.34% and closed UP +0.01%; the iShares NASDAQ Biotechnology (IBB) did NOT indicate in the pre-open and closed UP +0.57%.

 

 

At the close …

3 biggest $ gainers included:

  • Cellectis SA (CLLS) +$0.62;
  • AxoGen (AXGN) +$0.50;
  • Organovo (ONVO) +$0.40;

 

The 3 biggest $ losers of the session were:

  • Bluebird bio (BLUE) -$1.45 after Monday’s -$0.50
  • Kite Pharma (KITE) -$1.23 after Monday’s +$1.95;
  • Stemline (STML) -$0.55 after Monday’s -$1.10;

 

 

The downside trend reflects a pricing trend range of:

  • Tuesday’s decliners ranged from -0.64% <CYTX> to -14.19% <ISCO> in 19 equities;
  • Monday’s decliners ranged from -0.00% <BCLI> to -19.83% <OPXA> in 27 equities;

 

The upside shows a pricing trend range of:

  • Tuesday’s gainers ranged from +0.63% to +10.80% in 22 equities;
  • Monday’s gainers ranged from +0.63% <CLLS> to +12.29% <CUR> in 14 equities

 

Wrap-up: anybody can read a paragraph … review the percentage changes per day in the week of the decliners and advancers while …

  • Monday’s 14 gainers compared to Tuesday’s 22 …
  • Monday’s 27 decliners compared to Tuesday’s 19 …

 

 

Pre-open indication’s tally:  7 hits (AGTC, BSTG, BTX, HSGX, XON and ONVO) and 1 miss (FATE)

  • Applied Genetic Technologies (AGTC) closed UP +$0.10 – hit;
  • Asterias Biotherapeutics (NYSEMKT: AST) closed UP +$0.10 – hit;
  • Biostage (BSTG) closed UP +$0.02 – hit;
  • BioTime (NYSEMKT: BTX) closed UP +$0.17 – hit;
  • Fate Therapeutics (FATE) closed DOWN -$0.08 – miss;
  • Histogenics (HSGX) closed DOWN -$0.08 – hit;
  • Intrexon (XON) closed UP +$0.28 – hit;
  • Organovo (ONVO) closed UP +$0.40 – hit;

 

 

Percentage (%) decliners:

  • International Stem Cell (ISCO) -14.19% after Monday’s -7.74%;
  • Fibrocell (FCSC) -13%;
  • ReNeuron (RENE.L) -12% after Monday’s +4.17%;
  • Opexa (OPXA) -6.12% after Monday’s -19.83%;
  • Caladrius Biosciences (CLBS) -5.13%

 

 

Percentage (%) advancers:

  • Organovo (ONVO) +11.80%;
  • Northwest Bio (NWBO) +10.66% after Monday’s +3.17%;
  • Mesoblast (MESO) +6.45% after Monday’s +10.25%;
  • Sangamo (SGMO) +6.56%;
  • AxoGen (AXGN) +5.95%

 

 

Flat:                                                                                                      

  • Adverum (ADVM) at $2.95;
  • Brainstorm (BCLI) at $2.15;
  • Cesca Therapeutics (KOOL) at $2.98

 

 

Review my fear gauge or the CBOE Volatility Index (VIX):

·         Tuesday traded near 12.7;

·         Monday traded near 12.64;

·         Friday traded near 11.8;

·         Thursday traded 12.64;

·         Wednesday traded near 17.22;

·         Last Tuesday traded near 11.63;

 

                                                                                                                                                                                               

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.